Meta Information

ID:tesamorelin

Name:Tesamorelin

Schema Version:1.5

Title

Tesamorelin

Alternate Names

• Egrifta

Intervention Type

therapeutic_agent

Expected Cost Mean

Low Cost:

2000

High Cost:

5000

Cost Type:

monthly

Description:

Prescription cost for brand-name drug; insurance coverage is highly variable.

Summary

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to release endogenous growth hormone. Its primary healthspan relevance is its proven, potent ability to selectively reduce visceral adipose tissue (VAT), a key driver of age-related metabolic dysfunction and systemic inflammation. It may also offer secondary benefits for cognitive function in older adults by increasing levels of GABA and other neurochemicals.

Purpose

A GHRH analog that reduces visceral fat and may improve cognition.

Card Summary

Reduces visceral fat by stimulating natural growth hormone release.

Drug Class

ghrh-analogs

Drugs In Class

Empty Array

Impact

Score:

7.2

Justification:

Highly effective at reducing visceral adipose tissue, a key metabolic health driver.

Evidence

Grade:

A

Score:

9

Justification:

Multiple human RCTs confirm significant reduction in visceral adipose tissue.

Safety

Score:

6.5

Justification:

Requires prescription and monitoring; can impact glucose metabolism and cause joint pain.

Flags

• Requires a prescription and ongoing medical supervision.
• May increase IGF-1 levels, with unknown long-term effects on cancer risk.
• Can negatively impact insulin sensitivity and blood glucose control.
• Contraindicated in individuals with active malignancy.
• Common side effects include joint pain (arthralgia) and fluid retention.

Verdict

A powerful, targeted tool for visceral fat reduction under medical supervision.

Created

2026-04-24T00:13:29.872723Z

Model

Gemini 3.1 Pro (High)

Delivery

Route:

subcutaneous_injection

Scope:

• systemic

Indication

Focus:

healthspan

Description:

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to release endogenous growth hormone. Its primary healthspan relevance is its proven, p...

Typical Protocol

• 1 mg daily via subcutaneous injection, often cycled 5 days on, 2 days off.